基于线粒体损伤机制的药物性急性肾损伤研究进展

doi:10.12092/j.issn.1009-2501.2018.05.016

摘要/Abstract

摘要：

药物性肾损伤约占急性肾损伤发病率的20%，易发展为肾衰竭。目前临床除了肾脏替代疗法，尚无有效的治疗措施。越来越多的证据表明线粒体结构和功能损伤在药物性急性肾损伤的发生发展中发挥了重要作用。本文就药物性急性肾损伤领域中线粒体损伤的相关机制、潜在的生物标志物以及可能的干预靶点的研究进展作一综述，以期为临床上药物性急性肾损伤的早期诊断和治疗提供新的思路。

关键词: 药物性急性肾损伤, 线粒体损伤, 肾毒性

Abstract:

Drug-induced kidney injury accounts for roughly 20% of acute kidney injury (AKI), which is likely to progress into chronic renal failure. Currently, there are no available strategies except renal replacement therapy for drug-induced AKI. Accumulating evidence highlights mitochondrial structure abnormal and dysfunction contribute greatly to the onset and progression of drug-induced AKI. This review covers the research progress on the role of mitochondrial damage in drug-induced AKI, and also proposes potential biomarkers and intervention targets, which will provide new ideas for early diagnosis and treatment of drug-induced AKI.

Key words: drug-induced acute kidney injury, mitochondrial damage, nephrotoxicity

中图分类号:

R692

蔡名敏，姚澜，张经纬，周芳，王广基. 基于线粒体损伤机制的药物性急性肾损伤研究进展[J]. 中国临床药理学与治疗学, 2018, 23(5): 578-585.

CAI Mingmin，YAO Lan，ZHANG Jingwei，ZHOU Fang，WANG Guangji. Research progress in drug-induced acute kidney injury based on mitochondrial damage[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 578-585.

参考文献

［1］Hosohata K.Role of oxidative stress in drug-induced kidney injury［J］.Int J Mol Sci, 2016, 17(11)：pii: E1826.
［2］Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: The PICARD experience［J］. Kidney Int, 2004, 66(4): 1613-1621.
［3］Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients-A multinational, multicenter study［J］. JAMA, 2005, 294(7): 813-818.
［4］Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically Ill patients with acute kidney injury: The ELAIN randomized clinical trial［J］. JAMA, 2016, 315(20): 2190.
［5］Uchino S. The epidemiology of acute renal failure in the world［J］. Curr Opin Crit Care, 2006, 12(6): 538.
［6］Yang Y, Song M, Liu Y, et al.Renoprotective approaches and strategies in acute kidney injury［J］. Pharmacol Ther, 2016, 163: 58-73.
［7］Gary NE, Buzzeo L, Salaki J, et al. Gentamicin-associated acute renal failure［J］. Arch Intern Med, 1976, 136(10): 1101-1104.
［8］Suzuki T, Yamaguchi H, Ogura J, et al. Megalin contributes to kidney accumulation and nephrotoxicity of colistin［J］. Antimicrob Agents Chemother, 2013, 57(12): 6319-6324.
［9］Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Lopez-Novoa JM, et al. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity［J］. Crit Rev Toxicol, 2011, 41(10): 803-821.
［10］Ozkok A，Edelstein CL.Pathophysiology of cisplatin-induced acute kidney injury［J］. Biomed Res Int, 2014, 2014: 967826.
［11］连燕娜，高丽萍. 益气补肾方药对顺铂致大鼠肾毒性及顺铂抗肿瘤活性的影响［J］.中国临床药理学与治疗学, 2016, 21(1): 50-54.
［12］Aleksa K, Matsell D, Krausz K, et al. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity［J］. Pediatric Nephrology, 2005, 20(7): 872-885.
［13］Whiting PH, Thomson AW, Blair JT, et al. Experimental cyclosporin A nephrotoxicity［J］. Br J Exp Pathol, 1982, 63(1): 88-94.
［14］Wijnen RM, Ericzon BG, Tiebosch AT, et al. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study［J］. Transpl Int，1992, 5 Suppl 1(5 Suppl 1): S454-458.
［15］Izzedine H, Launay-Vacher V，Deray G. Antiviral drug-induced nephrotoxicity［J］. Am J Kidney Dis, 2005, 45(5): 804-817.
［16］程诗佳，王崇. 替比夫定、恩替卡韦、替诺福韦治疗慢性乙型肝炎患者的肾脏安全性及有效性的对比［J］. 临床肝胆病杂志, 2015,31(7): 1054.
［17］Depierreux M, Damme BV, Houte KV, et al.Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs［J］. Am J Kidney Dis, 1994, 24(2): 172-180.
［18］Inoue M, Akimoto T, Saito O, et al. Successful relatively low-dose corticosteroid therapy for diclofenac-induced acute interstitial nephritis with severe renal failure［J］. Clin Exp Nephrol, 2008, 12(4): 296-299.
［19］Jones B, Hewson E，Price A. Acute interstitial nephritis due to omeprazole［J］. Lancet, 1994, 344(8928): 1017-1018.
［20］Nagai J，Takano M. Entry of aminoglycosides into renal tubular epithelial cells via endocytosisdependent and endocytosis-independent pathways［J］. Biochem Pharmacol, 2014, 90(4): 331-337.
［21］Moestrup SK, Cui S, Vorum H, et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs［J］. J Clin Invest, 1995,96(3):1404-1413.
［22］Tauris J, Christensen EI, Nykjaer A, et al. Cubilin and megalin co-localize in the neonatal inner ear［J］. Audiol Neurootol, 2009, 14(4): 267-278.
［23］Lebeau C, Arlt VM, Schmeiser HH, et al. Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells［J］. Kidney Int, 2001, 60(4): 1332-1342.
［24］Ciarimboli G, Deuster D, Knief A, et al. Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto-and Nephrotoxicity and Is a Target for Protective Interventions［J］.Am J Pathol, 2010, 176(3): 1169-1180.
［25］Yang Y, Liu H, Liu F, et al. Mitochondrial dysregulation and protection in cisplatin nephrotoxicity［J］. Arch Toxicol, 2014, 88(6): 1249-1256.
［26］Visarius TM, Putt DA, Schare JM, et al. Pathways of glutathione metabolism and transport in isolated proximal tubular cells from rat kidney［J］. Biochem Pharmacol, 1996, 52(2): 259-272.
［27］Emma F, Montini G, Parikh SM, et al. Mitochondrial dysfunction in inherited renal disease and acute kidney injury［J］. Nat Rev Nephrol, 2016, 12(5): 267-280.
［28］Morales AI, Detaille D, Prieto M, et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondriadependent pathway［J］. Kidney Int, 2010, 77(10): 861-869.
［29］Lopez-Novoa JM, Quiros Y, Vicente L, et al. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view［J］. Kidney Int, 2011, 79(1): 33-45.
［30］Zhan M, Brooks C, Liu F, et al. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology［J］. Kidney Int, 2013, 83(4): 568-581.
［31］Brooks C, Wei Q, Cho SG, et al. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models［J］. J Clin Invest, 2009, 119(5): 1275-1285.
［32］Ishimoto Y，Inagi R. Mitochondria: a therapeutic target in acute kidney injury［J］. Nephrol Dial Transplant, 2016, 31(7): 1062-1069.
［33］Zhao C, Chen Z, Qi J, et al. Drp1-dependent mitophagy protects against cisplatin-induced apoptosis of renal tubular epithelial cells by improving mitochondrial function［J］. Oncotarget, 2017, 8(13): 20988-21000.
［34］Pagliarini DJ, Calvo SE, Chang B, et al. A mitochondrial protein compendium elucidates complex I disease biology［J］. Cell, 2008, 134(1): 112-123.
［35］Ralto KM，Parikh SM. Mitochondria in acute kidney injury［J］. Semin Nephrol, 2016, 36(1): 8-16.
［36］Morigi M,Perico L, Rota C, et al. Sirtuin 3dependent mitochondrial dynamic improvements protect against acute kidney injury［J］. J Clin Invest, 2015, 125(2): 715-726.
［37］Tran M, Tam D, Bardia A, et al. PGC-1 alpha promotes recovery after acute kidney injury during systemic inflammation in mice［J］. J Clin Invest, 2011, 121(10): 4003-4014.
［38］Rasbach KA，Schnellmann RG. PGC-1 alpha over-expression promotes recovery from mitochondrial dysfunction and cell injury［J］. Biochem Biophys Res Commun, 2007, 355(3): 734-739.
［39］Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities［J］. Kidney Int, 2010, 78(11): 1171-1177.
［40］Ramamoorthy H, Abraham P，Isaac B. Mitochondrial dysfunction and electron transport chain complex defect in a rat model of tenofovir disoproxil fumarate nephrotoxicity［J］. J Biochem Mol Toxicol, 2014, 28(6): 246-255.
［41］Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion［J］. Human Pathology, 2001, 32(7): 734-740.
［42］Jiang Z, Bao Q, Sun L, et al. Possible role of mtDNA depletion and respiratory chain defects in aristolochic acid I-induced acute nephrotoxicity［J］. Toxicol Appl Pharmacol, 2013, 266(2): 198-203.
［43］Zager RA, Johnson AC, Hanson SY. Radiographic contrast media-induced tubular injury: Evaluation of oxidant stress and plasma membrane integrity［J］. Kidney Int, 2003, 64(1): 128-139.
［44］Zager RA, Johnson AC, Hanson SY. Proximal tubular cytochrome c efflux: determinant, and potential marker, of mitochondrial injury［J］. Kidney Int, 2004, 65(6): 2123-2134.
［45］Small DM，Gobe GC. Cytochrome c: potential as a noninvasive biomarker of drug-induced acute kidney injury［J］. Expert Opin Drug Metab Toxicol，2012, 8(6): 655-664.
［46］Funk JA，Schnellmann RG. Persistent disruption of mitochondrial homeostasis after acute kidney injury［J］. Am J Physiol Renal Physiol, 2012, 302(7): F853-864.
［47］Whitaker RM, Korrapati MC, Stallons LJ, et al. Urinary ATP synthase subunit beta is a novel biomarker of renal mitochondrial dysfunction in acute kidney injury［J］. Toxicol Sci, 2015, 145(1): 108-117.
［48］Whitaker RM, Stallons LJ, Kneff JE, et al. Urinary mitochondrial DNA is a biomarker of mitochondrial disruption and renal dysfunction in acute kidney injury［J］. Kidney Int, 2015, 88(6): 1336-1344.
［49］Hu Q, Ren J, Wu J, et al. Urinary mitochondrial DNA levels identify acute kidney injury in surgical critical illness patients［J］. Shock, 2017, 48(1): 11-17.
［50］何睦, 姚卫峰, 蔡秀江, 等.代谢组学在肝肾损伤研究中的应用［J］.中国临床药理学与治疗学, 2012, 17(8): 924-920.
［51］Wen XY, Peng ZY, Li YJ, et al.One dose of cyclosporine A is protective at initiation of folic acidinduced acute kidney injury in mice［J］. Nephrol Dial Transplant, 2012, 27(8): 3100-3109.
［52］Wang Z, Bao H, Ge Y, et al. Pharmacological targeting of GSK3beta confers protection against podocytopathy and proteinuria by desensitizing mitochondrial permeability transition［J］. Br J Pharmacol, 2015, 172(3): 895-909.
［53］Plotnikov EY, Chupyrkina AA, Jankauskas SS, et al. Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion［J］. Biochim Biophys Acta, 2011, 1812(1): 77-86.
［54］Jankauskas SS, Plotnikov EY, Morosanova MA, et al. Mitochondria-targeted antioxidant SkQR1 ameliorates gentamycin-induced renal failure and hearing loss［J］. Biochemistry (Mosc), 2012, 77(6): 666-670.
［55］Mukhopadhyay P, Horvath B, Zsengeller Z, et al. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy［J］. Free Radic Biol Med, 2012, 52(2): 497-506.
［56］Brenmoehl J，Hoeflich A. Dual control of mitochondrial biogenesis by sirtuin 1 and sirtuin 3［J］. Mitochondrion, 2013, 13(6): 755-761.
［57］Funk JA，Schnellmann RG. Accelerated recovery of renal mitochondrial and tubule homeostasis with SIRT1/PGC-1alpha activation following ischemia-reperfusion injury［J］.Toxicol Appl Pharmacol, 2013, 273(2): 345-354.
［58］Wills LP, Trager RE, Beeson GC, et al. The beta(2)-Adrenoceptor Agonist Formoterol Stimulates Mitochondrial Biogenesis［J］. J Pharmacol Exp Ther, 2012, 342(1): 106-118.
［59］Jesinkey SR, Funk JA, Stallons LJ, et al. Formoterol restores mitochondrial and renal function after ischemia-reperfusion injury［J］. J Am Soc Nephrol, 2014, 25(6): 1157-1162.

[1]	王新丽, 许霞青, 方寒冰, 郭玉忠. 佛波酯增强顺铂的抗肿瘤活性及降低其肾毒性的作用研究[J]. 中国临床药理学与治疗学, 2022, 27(5): 535-543.
[2]	连燕娜，高丽萍. 益气补肾方药对顺铂致大鼠肾毒性及顺铂抗肿瘤活性的影响[J]. 中国临床药理学与治疗学, 2016, 21(1): 50-54.
[3]	孙晨, 奇锦峰, 余文浩, 王永辉, 林梅, 张娜. 肉桂等八种中药对小鼠肾脏三种主要有机阴离子转运体的影响[J]. 中国临床药理学与治疗学, 2015, 20(9): 985-992.
[4]	孙潇潇, 邵华, 王友群. 万古霉素的肾毒性研究进展[J]. 中国临床药理学与治疗学, 2014, 19(5): 597-600.
[5]	金婉冰. 葛根素对庆大霉素致大鼠肾毒性的保护作用[J]. 中国临床药理学与治疗学, 2013, 18(8): 864-867.
[6]	吴立平, 黎七雄. 槲皮素对环孢素A 所致肾毒性的保护作用[J]. 中国临床药理学与治疗学, 2007, 12(6): 659-667.
[7]	黄云剑, 瘳立生. 阿魏酸钠对培养近端肾小管细胞庆大霉素毒性保护机理探讨[J]. 中国临床药理学与治疗学, 1997, 2(1): 37-39.